Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Sell
17
BIXT Quote, Financials, Valuation and Earnings
Last price:
$0.1100
Seasonality move
:
10.23%
Day range:
$0.1002 - $0.1099
52-week range:
$0.0615 - $0.2283
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
60.26x
P/B ratio:
--
Volume:
91.8K
Avg. volume:
189.2K
1-year change:
-1.87%
Market cap:
$9.6M
Revenue:
--
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bioxytran has -- downside to fair value with a price target of -- per share.
BIXT vs. S&P 500
-
Over the past 5 trading days, Bioxytran has underperformed the S&P 500 by -19.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioxytran does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioxytran has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bioxytran reported revenues of --.
Earnings Growth
-
Bioxytran earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bioxytran reported earnings per share of -$0.02.
Enterprise value:
10.9M
EV / Invested capital:
--
Price / LTM sales:
60.26x
EV / EBIT:
--
EV / Revenue:
50.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-80.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$2.4M | -$3.8M | -$2M | -$781.3K | -$517K | |
| EBITDA | -$2.2M | -$3.8M | -$2.1M | -$544K | -$1.3M | |
| Diluted EPS | -$0.03 | -$0.02 | -$0.04 | -- | -$0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $366.4K | $739.6K | $153.8K | $10K | $4.4K | |
| Total Assets | $385.3K | $807.9K | $233.5K | $125.5K | $136.1K | |
| Current Liabilities | $2.9M | $4.9M | $4.3M | $1.1M | $2.8M | |
| Total Liabilities | $2.9M | $4.9M | $4.3M | $1.1M | $2.8M | |
| Total Equity | -$2.5M | -$4.1M | -$4.1M | -$990.4K | -$2.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.3M | -$698.1K | -$113.5K | -$109.6K | -$167.3K | |
| Cash From Investing | -$14.6K | -$45.6K | -$22.2K | -$6K | -$20 | |
| Cash From Financing | $728K | $599.9K | $130K | $99.5K | $166.5K | |
| Free Cash Flow | -$1.3M | -$743.6K | -$135.7K | -$115.6K | -$167.3K | |
BIXT
Sector
Market Cap
$9.6M
$33.4M
Price % of 52-Week High
47.28%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-1.87%
-37.4%
Beta (5-Year)
1.791
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.1255
200-day SMA
Sell
Level
$0.1116
Bollinger Bands (100)
Sell
Level
0.0993 - 0.1593
Chaikin Money Flow
Sell
Level
-7.5M
20-day SMA
Sell
Level
$0.1372
Relative Strength Index (RSI14)
Sell
Level
35.7340
ADX Line
Sell
Level
19.8182
Williams %R
Buy
Level
-81.8553
50-day SMA
Sell
Level
$0.1475
MACD (12, 26)
Sell
Level
-0.0076
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-2.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Stock Forecast FAQ
In the current month, BIXT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIXT average analyst price target in the past 3 months is --.
-
Where Will Bioxytran Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioxytran share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Bioxytran?
Analysts are divided on their view about Bioxytran share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bioxytran is a Sell and believe this share price will rise from its current level to --.
-
What Is Bioxytran's Price Target?
The price target for Bioxytran over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIXT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioxytran is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BIXT?
You can purchase shares of Bioxytran via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioxytran shares.
-
What Is The Bioxytran Share Price Today?
Bioxytran was last trading at $0.1100 per share. This represents the most recent stock quote for Bioxytran. Yesterday, Bioxytran closed at $0.1079 per share.
-
How To Buy Bioxytran Stock Online?
In order to purchase Bioxytran stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TTD The Big Winner If Pharma Ads Are Banned?
Last week, Senators Bernie Sanders and Angus King introduced a…
Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
